Backgrounds
Methods
Criteria for considering studies for this review
Study outcomes
Search methods for studies: electronic searches
Data collection and analysis
Data extraction and management
Risk of bias assessment and data analysis
Results
Inclusion/exclusion criteria of studies
First author, year | Type of study | Method | Number of patients | Inclusion criteria | Exclusion criteria | Outcomes | Risk of bias according to Cochrane risk of bias tools |
---|---|---|---|---|---|---|---|
Agostini, 2006 | RCT | LAVH vs. VH | 48 | Benign uterine diseases, uterine size below pubis, favorable to BSO† | Adnexal mass | Operative data, complications | high |
Allam, 2015 | RCT | TAH vs.TLH vs. VH | 60 | Benign uterine diseases | Malignancy | Operative data, complications | unclear |
Candiani, 2009 | RCT | TLH vs. VH | 47 | Benign uterine diseases | Malignancy, estimated uterine volume > 300 mL, POP‡, ovarian pathology, PID§, endometriosis | Operative data, complications | high |
Darai, 2001 | RCT | LAVH vs. VH | 80 | Estimated uterine size > 280 g, contraindications to VH | Malignancy | Operative data, complications | high |
Drahonovsky, 2010 | RCT | LAVH vs. TLH vs. VH | 125 | Benign uterine diseases | Impossible VH, prior abdominal surgery, endometriosis, medical disorders | Operative data, complications | high |
Eggemann, 2018 | RCT | LAVH vs. VH | 192 | Benign uterine diseases, possible VH | Malignancy, POP‡, medical disorders | Operative data, complications | high |
Garry, 2014 | RCT | Unspecified LH vs. VH | 504 | Benign uterine diseases | Malignancy, POP‡, uterine size > 12 week gestation | Operative data, complications | high |
Ghezzi, 2010 | RCT | TLH vs. VH | 82 | Benign uterine diseases | Malignancy, POP‡, uterine size > 14 week gestation, large adnexal mass | Operative data, complications | high |
Hwang, 2002 | RCT | LAVH, vs. TAH vs. VH | 60 | Myoma > 8 cm | other benign gynecological conditions except myoma | Operative data, complications | high |
Mohammed, 2017 | RCT | LAVH vs. VH | 50 | Benign uterine diseases, age (40–70 years), estimated uterine weight < 280 g | BMI > 30, endometriosis, previous myomectomy, medical disorder | Operative data, complications | unclear |
Ottosen, 2000 | RCT | LAVH vs. TAH vs. VH | 80 | Benign uterine disease, myoma < 15 cm | Malignancy, uterine size > 16 week gestation, ovarian pathology, dense pelvic adhesion, possible VH | Operative data, complications | high |
Ribeiro, 2003 | RCT | TAH vs. TLH vs. VH | 40 | Benign uterine diseases | Estimated uterine volume > 400 cm3, medical disorders | Operative data, complications, inflammatory response | high |
Roy, 2011 | RCT | LAVH vs. TLH vs. VH | 90 | Benign uterine diseases, estimated uterine weight < 400 g | Malignancy, PID§, POP‡ | Operative data, complications | high |
Soriano, 2001 | RCT | LAVH vs. VH | 77 | Estimated uterine size > 280 g, contraindications to VH | Malignancy | Operative data, complications | high |
Sesti, 2014 | RCT | LAVH vs. TLH vs. VH | 108 | Symptomatic myoma, age < 55 years, uterine size > 12 week gestation | Malignancy, nulliparity, uterine size > 16 week gestation, previous uterine surgery, | Operative data, complications | low |
Sesti, 2008 | RCT | LAVH vs. TLH vs. VH | 100 | Symptomatic myoma, age < 55 years, uterine size > 12 week gestation | Malignancy, nulliparity, uterine size > 16 week gestation, previous uterine surgery, | Operative data, complication | unclear |
Sesti, 2008 | RCT | LAVH vs. VH | 80 | Symptomatic myoma, age < 55 years, uterine size > 12 week gestation | Malignancy, nulliparity, uterine size > 16 week gestation, previous uterine surgery, | Operative data, complication | unclear |
Zhu, 2009 | RCT | LAVH vs. VH | 69 | Benign uterine diseases | Malignancy | Operative data, complication | high |
Primary outcome
First author, year | VH(n) | Overall complications | Grade I complications | Grade II complications | Grade III complications | LH(n) | Overall complications | Grade I complications | Grade II complications | Grade III complications |
---|---|---|---|---|---|---|---|---|---|---|
Agostini, 2006 | 24 | 1 | Vault hematoma [1] | 0 | 0 | 24 | 3 | 0 | 0 | |
Allam, 2015 | 30 | 9 | Vault hematoma [2] | Transfusion [6] | Ureteral injury [1] | 30 | 1 | 0 | Transfusion [1] | 0 |
Candiani, 2009 | 30 | 6 | Fever [5] | DVT† [1] | 0 | 30 | 3 | Fever [3] | ||
Darai, 2001 | 40 | 5 | Transfusion [1] | 0 | 40 | 9 | Transfusion [1] | Cystotomy [1] | ||
Drahonovsky, 2010 | 40 | 20 | Fever [8], vault hematoma [10] | Transfusion [1] | Cystotomy [1] | 85 | 25 | vault hematoma [9] | Transfusion [1] | Cystotomy [1] |
Eggemann, 2018 | 97 | 3 | Fever [1] | Transfusion [1] | Cystotomy [1] | 95 | 3 | Fever [1] | Transfusion [1] | Cystotomy [1] |
Garry, 2004 | 168 | 65 | Transfusion [14] | Cystotomy [2] | 336 | 123 | Transfusion (39) | Cystotomy [3] Pulmonary embolism [2] | ||
Ghezzi, 2010 | 41 | 4 | Fever [2], urinary retention [2] | 0 | 0 | 41 | 1 | Urinary retention [1] | 0 | 0 |
Hwang, 2002 | 30 | 5 | Fever [4] | Transfusion [1] | 0 | 30 | 6 | UTI‡ [1] | Transfusion [5] | 0 |
Mohammed, 2017 | 25 | 4 | 0 | Transfusion [2] | Cystotomy [2] | 25 | 6 | 0 | Transfusion [4] | Cystotomy [2] |
Ottosen, 2000 | 40 | 7 | 0 | 40 | 4 | 0 | Reoperation [1] | |||
Ribeiro, 2003 | 20 | 1 | 0 | 0 | Cystotomy [1] | 20 | 0 | 0 | 0 | 0 |
Roy, 2011 | 30 | 8 | Fever [4], vaginal bleeding [4] | 0 | 0 | 60 | 22 | wound infection [2] | 0 | 0 |
Sesti, 2014 | 36 | 1 | Fever [1] | 0 | 0 | 72 | 5 | Transfusion [2] | 0 | |
Soriano, 2001 | 35 | 1 | 0 | Transfusion [1] | 0 | 37 | 1 | 0 | Transfusion [1] | 0 |
Secondary outcomes
Assessment of the quality of evidence
Certainty assessment | Number of patients | Effect | Certainty | Importance | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Number of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | LH | VH | Relative (95% CI) | Absolute (95% CI) | ||
Overall complications | ||||||||||||
17 | randomised trials | serious† | not serious | not serious | not serious | none | 169/887 (19.1%) | 212/1055 (20.1%) | RR 1.11 (0.85 to 1.45) | 22 more per 1000 (from 30 fewer to 90 more) | ⨁⨁⨁◯ MODERATE | none |
Grade I complications | ||||||||||||
17 | randomised trials | serious† | not serious | not serious | not serious | none | 128/887 (14.4%) | 144/1055 (13.6%) | RR 1.20 (0.90 to 1.61) | 27 more per 1000 (from 14 fewer to 83 more) | ⨁⨁⨁◯ MODERATE | none |
Grade II complications | ||||||||||||
17 | randomised trials | serious† | not serious | not serious | not serious | none | 29/887 (3.3%) | 55/1055 (5.2%) | RR 0.78 (0.49 to 1.24) | 11 fewer per 1000 (from 13 more to 27 fewer) | ⨁⨁⨁◯ MODERATE | none |
Grade III complications | ||||||||||||
17 | randomised trials | serious† | not serious | not serious | not serious | none | 12/887 (1.4%) | 14/1055 (1.3%) | RR 1.03 (0.49 to 2.16) | 0 fewer per 1000 (from 7 fewer to 15 more) | ⨁⨁⨁◯ MODERATE | none |
Urinary tract injuries | ||||||||||||
17 | randomised trials | serious† | not serious | not serious | not serious | none | 9/781 (1.2%) | 10/1020 (1.0%) | RR 1.20 (0.50 to 2.85) | 2 more per 1000 (from 5 fewer to 18 more) | ⨁⨁⨁◯ MODERATE | none |
Operating time | ||||||||||||
18 | randomised trials | serious† | not serious | not serious | not serious | none | 922 | 1089 | – | MD 34.01 h lower (45.54 lower to 24.48 lower) | ⨁⨁⨁◯ MODERATE | none |
Length of hospital stay | ||||||||||||
14 | randomised trials | serious‡ | serious§c | not serious | not serious | none | 636 | 809 | – | MD 6.57 h lower (18.65 lower to 5.5 higher) | ⨁⨁◯◯ LOW | none |
Blood loss | ||||||||||||
16 | randomised trials | serious† | serious§ | not serious | not serious | none | 595 | 598 | – | MD 35.91 mL lower (102.26 lower to 30.43 higher) | ⨁⨁◯◯ LOW | none |
Intraoperative conversion | ||||||||||||
7 | randomised trials | serious† | not serious | not serious | not serious | none | 15/771 (1.9%) | 24/939 (2.6%) | RR 0.94 (0.49 to 1.81) | 2 fewer per 1000 (from 13 fewer to 21 more) | ⨁⨁⨁◯ MODERATE | none |
Recuperation | ||||||||||||
4 | randomised trials | serious‡ | serious§ | not serious | not serious | none | 130 | 130 | – | MD 0.66 days higher (0.77 lower to 0.9 higher) | ⨁⨁◯◯ LOW | none |
Pain on day of surgery (assessed with: Visual analogue scale) | ||||||||||||
5 | randomised trials | serious† | not serious | not serious | not serious | none | 325 | 491 | – | MD 0.8 higher (0.08 lower to 1.68 higher) | ⨁⨁⨁◯ MODERATE | none |
Pain at 24 h after surgery (assessed with: Visual analogue scale) | ||||||||||||
4 | randomised trials | serious† | not serious | not serious | not serious | none | 155 | 157 | – | MD 0.53 lower (0.7 lower to 0.35 lower) | ⨁⨁⨁◯ MODERATE | none |
Pain at 48 h after surgery (assessed with: Visual analogue scale) | ||||||||||||
4 | randomised trials | serious† | not serious | not serious | not serious | none | 295 | 461 | – | MD 0.2 lower (0.61 lower to 0.22 higher) | ⨁⨁⨁◯ MODERATE | none |